Table 1.

Baseline demographics and clinical characteristics.

Sex, n [%]
Male	1109 [65.5]
Female	584 [34.5]
Age [years]	35.5±11.7a
Body weight [kg]	54.7±10.8a
Duration of CD [years]	11.1±8.0a
CDAI scoreb	204.6±106.5a
Pretreatment drugs, n [%]
Anti-TNFα agent	1306 [77.1]
Aminosalicylates	1497 [88.4]
Corticosteroids	463 [27.3]
Immunomodulators	580 [34.3]
CD-related antibiotics	305 [18.0]
Others	7 [0.4]
Concomitant drugs, n [%]
Aminosalicylates	1437 [84.9]
Corticosteroids	320 [18.9]
Immunomodulators	526 [31.1]
Antimicrobials for CD treatment	196 [11.6]
Concomitant therapy, n [%]
Granulocyte adsorption apheresis	10 [0.6]
Enteral nutrition therapy	941 [55.6]
Intravenous nutrition therapy	124 [7.3]
Others	45 [2.7]
History of surgical operation, n [%]
No	819 [48.4]
Location of CD lesions, n [%]
Small bowel	154 [9.1]
Colon	232 [13.7]
Small bowel and colon	421 [24.9]
Other	12 [0.7]
Location of CD lesions,c, n[%]
Perianal lesions	824 [48.7]
Rectal	599 [35.4]
Gastroduodenal	163 [9.6]
Colon	1157 [68.3]
Jejunum	251 [14.8]
Ileum	1258 [74.3]
Other	45 [2.7]
Complications, n [%]
Liver disorders	72 [4.3]
Renal disorders	31 [1.8]
Circulatory disorders	44 [2.6]
Blood disorders	231 [13.6]
Respiratory disorders	49 [2.9]
Other	510 [30.1]
Crohn’s disease-related intestinal complications, n [%]
No	656 [38.7]
Yes	1035 [61.1]
Crohn’s disease-related extraintestinal complications, n [%]
No	1394 [82.3]
Yes	297 [17.5]

CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; TNF, tumour necrosis factor.

^aMean ± standard deviation [SD].

^bData in the effectiveness analysis set [n = 688].

^cData include both current and previous disease history.